ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-14 pm EST			5-day change	1st Jan Change
200.24 ^USD	-8.14%		-7.09%	-4.52%

Jan. 14	ICON Reaffirms 2024 Outlook, Provides 2025 Guidance; Shares Down Pre-Bell	MT
Jan. 08	Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative Disorders	CI

Baird Downgrades ICON to Neutral From Outperform, Price Target is $340

October 24, 2024 at 05:57 am EDT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about ICON Public Limited Company

ICON Reaffirms 2024 Outlook, Provides 2025 Guidance; Shares Down Pre-Bell	Jan. 14	MT
Icon plc Releases the Findings of A Survey of over 120 Biomarkers and Pharma Professionals Developing Treatments for Neurodegenerative Disorders	Jan. 08	CI
RBC Initiates ICON PLC at Outperform With $263 Price Target	Jan. 07	MT
Truist Securities Adjusts Price Target on ICON to $284 From $295, Keeps Buy Rating	Dec. 18	MT
ICON Names Barry Balfe Chief Operating Officer	Dec. 18	MT
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer	Dec. 18	CI
Nephron Upgrades ICON to Buy, Price Target is $280	Dec. 02	MT
Fed minutes and inflation data set to stir Thanksgiving week	Nov. 25
Analyst recommendations: Five Below, Robinhood, Snowflake, Block, Ge Vernova...	Nov. 25
ICON Public Limited Company Reiterates Earnings Guidance for the Year 2024 and Provides Revenue Guidance for 2025	Nov. 21	CI
ICON Public Seeks M&A	Nov. 21	CI
ICON Public Limited Company Presents at Jefferies London Healthcare Conference 2024, Nov-21-2024 08:00 AM	Nov. 21
ICON's 2026 High-Single-Digit Growth Potential Intact If Customer Hurdles Cleared, UBS Says	24-10-25	MT
UBS Adjusts Price Target on ICON to $290 From $380, Maintains Buy Rating	24-10-25	MT
ICON Public Limited Company announces an Equity Buyback for $250 million worth of its shares.	24-10-25	CI
ICON Shares Decline as Baird Downgrade Follows Q3 Miss	24-10-24	MT
Technology Stocks Rise After Tesla Earnings as US Equity Futures Trade Mixed Pre-Bell	24-10-24	MT
ICON Seeks M&A	24-10-24	CI
ICON Public Limited Company, Q3 2024 Earnings Call, Oct 24, 2024	24-10-24
Top Premarket Decliners	24-10-24	MT
Baird Downgrades ICON to Neutral From Outperform, Price Target is $340	24-10-24	MT
Analyst recommendations: P&G, Enphase, AT&T, Deckers Outdoor, ServiceNow...	24-10-24
Icon Shares Drop 17% After Missing on 3Q Results	24-10-23	DJ
ICON Q3 Adjusted EPS Increases, Revenue Falls; 2024 Outlook Lowered	24-10-23	MT
Earnings Flash (ICLR) ICON Posts Q3 EPS $3.35	24-10-23	MT

Chart ICON Public Limited Company

Duration

Period

ICLR: Dynamic Chart

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

42,250

Sector

Biotechnology & Medical Research

Calendar

06:45pm - JP Morgan Healthcare Conference

More about the company